Literature DB >> 7596120

Acute intravenous conversion of canine atrial flutter: comparison of antiarrhythmic agents.

L V Buchanan1, G Kabell, J K Gibson.   

Abstract

We studied the acute intravenous (i.v.) effects of the antiarrhythmic agents ibutilide, sematilide, lidocaine, and encainide in a canine Y-shaped right atrial incision model of atrial flutter. After baseline determination of atrial effective refractory period (AERP), sustained atrial flutter (AFL) was initiated by atrial pacing in 25 dogs. Each dog then received placebo, followed by sequential doses of a particular agent every 5 min until AFL was terminated or the highest dose was administered. Ibutilide increased AFL cycle length (CL: 26 +/- 6 ms) before termination of AFL in 8 of 8 dogs in 1 min after the effective dose (6 +/- 1 micrograms/kg). AERP determined immediately after termination of AFL was significantly increased (44 +/- 7 ms). AFL could not be reinitiated after termination with ibutilide. Sematilide increased AFL CL 12 +/- 6 ms, significantly increased AERP 25 +/- 6 ms, and terminated AFL in 4 of 8 dogs (0.6 +/- 0.2 mg/kg). After sematilide or pacing-induced termination, AFL was reinducible in only 1 dog. Lidocaine terminated AFL in 2 of 5 dogs (2.0 +/- 0.5 mg/kg). AERP was unchanged in both animals, and AFL CL increased by 37 +/- 3 ms. AFL was reinducible in all 5 lidocaine-treated dogs after AFL was terminated. Encainide terminated AFL in 3 of 4 dogs after a dose of 3.0 +/- 0.0 mg/kg. AERP was significantly increased 77 +/- 10 ms, and AFL CL was markedly increased by 226 +/- 11 ms. AFL could not be reinitiated after termination of AFL by encainide.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7596120     DOI: 10.1097/00005344-199504000-00005

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  3 in total

Review 1.  Ibutilide. A review of its pharmacological properties and clinical potential in the acute management of atrial flutter and fibrillation.

Authors:  R H Foster; M I Wilde; A Markham
Journal:  Drugs       Date:  1997-08       Impact factor: 9.546

2.  Pharmacologic enhancement of atrial electrical defibrillation efficacy: role of ibutilide.

Authors:  D S Khoury; M D Assar; H Sun
Journal:  J Interv Card Electrophysiol       Date:  1997-12       Impact factor: 1.900

3.  Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group.

Authors:  M A Vos; S R Golitsyn; K Stangl; M Y Ruda; L V Van Wijk; J D Harry; K T Perry; P Touboul; G Steinbeck; H J Wellens
Journal:  Heart       Date:  1998-06       Impact factor: 5.994

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.